Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Poole

Showing results (221-230 of 302) with videos related to

Pageof 31
Sort By:
Circulation|November 15, 1995
A prospective randomized evaluation of implantable cardioverter-defibrillator size on unipolar defibrillation system efficacyG K Jones, J E Poole, P J Kudenchuk, et al.
Circulation|March 15, 1995
Truncated biphasic pulses for transthoracic defibrillationG H Bardy, B E Gliner, P J Kudenchuk, et al.
Circulation|January 1, 1995
A prospective randomized comparison in humans of biphasic waveform 60-microF and 120-microF capacitance pulses using a unipolar defibrillation systemG H Bardy, J E Poole, P J Kudenchuk, et al.
Circulation. Arrhythmia and Electrophysiology|April 23, 2015
Response to Letter Regarding "REPLACE DARE (Death After Replacement Evaluation) Score: Determinants of All-Cause Mortality After Implantable Device Replacement Or Upgrade From the REPLACE Registry"Mina K Chung, Richard G Holcomb, Suneet Mittal, et al.
Heart Rhythm O2|August 25, 2020
QT interval and arrhythmic safety of hydroxychloroquine monotherapy in coronavirus disease 2019Arun R Sridhar, Neal A Chatterjee, Basil Saour, et al.
Heart Rhythm|November 27, 2010
Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)Jonathan P Piccini, Sana M Al-Khatib, Anne S Hellkamp, et al.
American Heart Journal|March 27, 2007
Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)Michael G Dickinson, John H Ip, Brian Olshansky, et al.
Heart Rhythm O2|June 11, 2021
AnaLysIs of Both sex and device specific factoRs on outcomes in pAtients with non-ischemic cardiomyopathy (BIO-LIBRA): Design and clinical protocolValentina Kutyifa, Mary W Brown, Christopher A Beck, et al.
Journal of the American College of Cardiology|July 9, 2021
Ablation Versus Drug Therapy for Atrial Fibrillation in Racial and Ethnic MinoritiesKevin L Thomas, Hussein R Al-Khalidi, Adam P Silverstein, et al.
Journal of the American College of Cardiology|April 15, 2014
Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial)Daniel P Fishbein, Anne S Hellkamp, Daniel B Mark, et al.
Pageof 31

Showing results (221-230 of 302) with videos related to

Sort By:
Pageof 31
Circulation|November 15, 1995
A prospective randomized evaluation of implantable cardioverter-defibrillator size on unipolar defibrillation system efficacyG K Jones, J E Poole, P J Kudenchuk, et al.
Circulation|March 15, 1995
Truncated biphasic pulses for transthoracic defibrillationG H Bardy, B E Gliner, P J Kudenchuk, et al.
Circulation|January 1, 1995
A prospective randomized comparison in humans of biphasic waveform 60-microF and 120-microF capacitance pulses using a unipolar defibrillation systemG H Bardy, J E Poole, P J Kudenchuk, et al.
Circulation. Arrhythmia and Electrophysiology|April 23, 2015
Response to Letter Regarding "REPLACE DARE (Death After Replacement Evaluation) Score: Determinants of All-Cause Mortality After Implantable Device Replacement Or Upgrade From the REPLACE Registry"Mina K Chung, Richard G Holcomb, Suneet Mittal, et al.
Heart Rhythm O2|August 25, 2020
QT interval and arrhythmic safety of hydroxychloroquine monotherapy in coronavirus disease 2019Arun R Sridhar, Neal A Chatterjee, Basil Saour, et al.
Heart Rhythm|November 27, 2010
Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)Jonathan P Piccini, Sana M Al-Khatib, Anne S Hellkamp, et al.
American Heart Journal|March 27, 2007
Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)Michael G Dickinson, John H Ip, Brian Olshansky, et al.
Heart Rhythm O2|June 11, 2021
AnaLysIs of Both sex and device specific factoRs on outcomes in pAtients with non-ischemic cardiomyopathy (BIO-LIBRA): Design and clinical protocolValentina Kutyifa, Mary W Brown, Christopher A Beck, et al.
Journal of the American College of Cardiology|July 9, 2021
Ablation Versus Drug Therapy for Atrial Fibrillation in Racial and Ethnic MinoritiesKevin L Thomas, Hussein R Al-Khalidi, Adam P Silverstein, et al.
Journal of the American College of Cardiology|April 15, 2014
Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial)Daniel P Fishbein, Anne S Hellkamp, Daniel B Mark, et al.
Pageof 31